Creating a new product to clean skin after chemical attacks
Development of a novel product for skin decontamination after exposure to chemical warfare agents
This study is testing a new skin cleaning product called Veriox® that helps keep people safe from harmful chemicals in case of an attack, making it easier for first responders to quickly help those affected.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Armis Biopharma, INC. NIH-funded |
| Lab location | 1 site (Fort Collins, United States) |
| Project ID | NIH-10678884 on NIH RePORTER |
What this research studies
This research focuses on developing a new skin decontamination product called Veriox® to protect civilians in the event of a chemical warfare attack. The product aims to provide first responders with a fast-acting and effective solution for decontaminating individuals exposed to harmful chemical agents. Veriox® is designed to be easily dispensed using standard equipment, allowing for rapid treatment of multiple people in emergency situations. Additionally, it breaks down into harmless substances, making it safer for both users and the environment.
Who could benefit from this research
Good fit: Ideal candidates for this research include first responders and civilians who may be at risk of exposure to chemical warfare agents.
Not a fit: Patients who are not involved in emergency response or who are not at risk of chemical exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the safety and effectiveness of decontamination efforts during chemical warfare incidents.
How similar studies have performed: While there have been advancements in decontamination methods, the specific formulation and application of Veriox® represents a novel approach in this field.
Where this research is happening
Fort Collins, United States
- Armis Biopharma, INC. — Fort Collins, United States (Active)
Researchers
- Principal investigator: Noblitt, Scott — Armis Biopharma, INC.
- Study coordinator: Noblitt, Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.